Immunohistochemical Profiles of LOXL-1, FBN1, TGF-β1, and COX-2 in Pseudoexfoliation Syndrome

References

• Elhawy E, Kamthan G, Dong CQ, Danias J. PEX syndrome, a systemic disorder with ocular manifestations. Hum Genomics 2012;6:22.[ PMID: 23157966]
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Naumann GOH. Ocular and systemic pseudoexfoliation syndrome. Am J Ophthalmol 2006;141:921–37. [ PMID: 16678509]
   PubMed Web of Science ®Google Scholar
• Ghosh M, Speakman JS. The origin of senile lens exfoliation. Can J Ophthalmol 1983;18:340–343. [ PMID: 6671154]
   PubMed Web of Science ®Google Scholar
• Kurowska AK, Kamińska A, Izdebska J, Szaflik JP, Szaflik J. PEX syndrome -a systemic disorder. Klin Oczna 2009;111:160–164. [ PMID: 19673450]
   PubMedGoogle Scholar
• Ringvold A. Epidemiology of glaucoma in northern Europe. Eur J Ophthalmol 1996;6:26–29. [ PMID: 8744847]
   PubMedGoogle Scholar
• Jonasson F, Damji KF, Arnarsson A, Sverrisson T, Wang L, Sasaki H et al. Prevalence of open-angle glaucoma in Iceland: Reykjavik Eye Study. Eye (Lond) 2003;17:747–753. [ PMID: 12928689]
   PubMed Web of Science ®Google Scholar
• Andrikopoulos GK, Mela EK, Georgakopoulos CD, Papadopoulos GE, Damelou AN, Gartaganis SP. et al. Pseudoexfoliation syndrome prevalence in Greek patients with cataract and its association to glaucoma and coronary artery disease. Eye (Lond) 2009;23:442–447. [ PMID: 17932505]
   PubMed Web of Science ®Google Scholar
• Kozobolis VP, Papatzanaki M, Vlachonikolis IG, Pallikaris IG, Tsambarlakis IG. Epidemiology of pseudoexfoliation in the island of Crete (Greece). Acta Ophthalmol Scand 1997;75:726–729. [ PMID: 9527341]
   PubMedGoogle Scholar
• Topouzis F, Wilson MR, Harris A, Anastasopoulos E, Yu F, Mavroudis L et al. Prevalence of open-angle glaucoma in Greece: the Thessaloniki Eye Study. Am J Ophthalmol 2007;144:511–519. [ PMID: 17893012]
   Web of Science ®Google Scholar
• Bengtsson B, Heijl A. A long-term prospective study of risk factors for glaucomatous visual field loss in patients with ocular hypertension. J Glaucoma 2005;14:135–138. [ PMID: 15741815]
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U. Genetics and genomics of PEX syndrome/glaucoma. Middle East Afr J Ophthalmol 2011;18:30–36. [ PMID: 21572731]
   PubMedGoogle Scholar
• Ritch R, Schlötzer-Schrehardt U. Exfoliation (pseudoexfoliation) syndrome: toward a new understanding. Proceedings of the First International Think Tank. Acta Ophthalmol Scand 200;79:213–217. [ PMID: 11284770]
   Google Scholar
• Schlötzer-Schrehardt U, von der Mark K, Sakai LY, Naumann GO. Increased extracellular deposition of fibrillin-containing fibrils in pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 1997;38:970–984. [ PMID: 9112993]
   PubMed Web of Science ®Google Scholar
• Ritch R, Schlötzer-Schrehardt U. Exfoliation syndrome. Surv Ophthalmol 2001;45:265–315. [ PMID: 11166342]
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Lommatzsch J, Küchle M, Konstas AG, Naumann GO. Matrix metalloproteinases and their inhibitors in aqueous humor of patients with pseudoexfoliation syndrome/glaucoma and primary open-angle glaucoma. Invest Ophthalmol Vis Sci 2003;44:1117–1125. [ PMID: 12601038]
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Zenkel M, Küchle M, Sakai LY, Naumann GO. Role of transforming growth factor-beta1 and its latent form binding protein in pseudoexfoliation syndrome. Exp Eye Res 2001;73:765–780. [ PMID 11846508]
   PubMed Web of Science ®Google Scholar
• Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. Receptor 1994;4:17–23. [ PMID: 8038702]
   PubMedGoogle Scholar
• Radi ZA, Render JA. The pathophysiologic role of cyclo-oxygenases in the eye. J Ocul Pharmacol Ther 2008;24:141–151. [ PMID: 18355129].
   PubMed Web of Science ®Google Scholar
• Yildirim Z, Yildirim F, Uçgun NI, Sepici-Dinçel A. The role of the cytokines in the pathogenesis of pseudoexfoliation syndrome. Int J Ophthalmol 2013;6:50–53. [ PMID: 23550261]
   PubMed Web of Science ®Google Scholar
• Karadimas SK, Klironomos G, Papachristou DJ, Papanikolaou S, Papadaki E, Gatzounis G. Immunohistochemical profile of NF-κB/p50, NF-κB/p65, MMP-9, MMP-2, and u-PA inexperimental cervical spondylotic myelopathy. Spine 2013;38:4–10 [ PMID: 22673181]
   PubMed Web of Science ®Google Scholar
• Schlötzer-Schrehardt U, Pasutto F, Sommer P, Hornstra I, Kruse FE, Naumann GO et al. Genotype-correlated expression of lysyl oxidase-like 1 in ocular tissues of patients with pseudoexfoliation syndrome/glaucoma and normal patients. Am J Pathol 2008;173:1724–1735. [ PMID: 18974306]
   PubMed Web of Science ®Google Scholar
• Kagan HM, Li W. Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell. J Cell Biochem 2003;88:660–672. [ PMID: 12577300]
   PubMed Web of Science ®Google Scholar
• Giampuzzi M et al. Lysyl oxidase activates the transcription activity of human collagen III promoter. Possible involvement of Ku antigen. J Biol Chem 2000;275:36341–36349. [ PMID: 10942761]
   PubMed Web of Science ®Google Scholar
• Laczko R, Szauter KM, Csiszar K. LOXL-1-Associated candidate epithelial pathomechanisms in exfoliation glaucoma. J Glaucoma 2014;23:S43–S47. [ PMID:25275905]
   PubMedGoogle Scholar
• Schlötzer-Schrehardt U. Molecular pathology of pseudoexfoliation syndrome/glaucoma-new insights from LOXL1 gene associations. Exp Eye Res 2009;88:776–785 [ PMID: 18809397]
   PubMed Web of Science ®Google Scholar
• Djordjević-Jocić J, Zlatanović G, Veselinović D, Jovanović P, Djordjević V, Zvezdanović L et al. Transforming growth factor beta1, matrix-metalloproteinase-2 and its tissue inhibitor in patients with pseudoexfoliation glaucoma/syndrome. Clin Ophthalmol 2014;8:305–309. [ PMID: 24511224]
   Google Scholar
• Gartaganis SP, Patsoukis NE, Nikolopoulos DK, Georgiou CD. Evidence for oxidative stress in lens epithelial cells in pseudoexfoliation syndrome. Eye 2007;21:1406–1411. [ PMID: 17001325]
   PubMed Web of Science ®Google Scholar
• Bocca C. et al. Expression of Cox-2 in human breast cancer cells as a critical determinant of epithelial-to-mesenchymal transition and invasiveness. Expert Opin Ther Targets. 2014;18:121–135 [ PMID:24325753]
   PubMed Web of Science ®Google Scholar
• Brookshire HL, English RV, Nadelstein B, Weigt AK, Gift BW, Gilger BC. Efficacy of COX-2 inhibitors in controlling inflammation and capsular opacification after phacoemulsification cataract removal. Vet Ophthalmol 2015;18:175–185 [ PMID: 24636042]
   PubMed Web of Science ®Google Scholar
• Fujii R et al. Restoration of E-cadherin expression by selective Cox-2 inhibition and the clinical relevance of the epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma. J Exp Clin Cancer Res 2014;33:40[ PMID:24887090]
   PubMed Web of Science ®Google Scholar
• Zenkel M, Krysta A, Pasutto F, Juenemann A, Kruse FE, Schlötzer-Schrehardt U. Regulation of lysyl oxidase-like 1 (LOXL1) and elastin-related genes by pathogenic factors associated with pseudoexfoliation syndrome. Invest Ophthalmol Vis Sci 2011;52:8488–8495. [ PMID: 21948647]
   PubMed Web of Science ®Google Scholar
• Klingberg F, Hinz B, White ES. The myofibroblast matrix: implications for tissue repair and fibrosis. J Pathol 2013;229:298–309. [ PMID: 22996908]
   PubMed Web of Science ®Google Scholar
• Kaartinen V, Warburton D. Fibrillin controls TGF-beta activation. Nat Genet 2003;33:331–332. [ PMID: 12610545]
   PubMed Web of Science ®Google Scholar
• Wipff J, Allanore Y, Boileau C. Interactions between fibrillin-1 and tgf-beta: consequences and human pathology. Med Sci (Paris) 2009;25:161–167.[ PMID: 19239848]
   PubMed Web of Science ®Google Scholar
• Rodríguez-Barbero A, Dorado F, Velasco S, Pandiella A, Banas B, López-Novoa JM. TGF-beta1 induces COX-2 expression and PGE2 synthesis through MAPK and PI3K pathways in human mesangial cells. Kidney Int 2006;70:901–909. [ PMID: 16820791]
   PubMed Web of Science ®Google Scholar